Day One Biopharmaceuticals Is A Biotechnology Company Focused On Developing Innovative Medicines For Childhood And Adult Cancers. Founded In 2018, The Company Aims To Address The Urgent Needs Of Pediatric Patients By Accelerating The Development Of Targeted Therapies. Their Mission Is To Change How New Treatments Reach Patients From The Moment Of Diagnosis. The Company Has A Portfolio That Includes Fda-approved Medicines Like Ojemda, Which Is Designed To Treat Relapsed Or Refractory Pediatric Low-grade Glioma. Day One Is Also Advancing Other Promising Candidates, Such As Tovorafenib And Day301, Targeting Various Cancers In Both Children And Adults. Their Team Consists Of Over 55 Professionals With Expertise In Medical, Clinical, And Research Oncology, All Dedicated To A Patient-centered Approach. Day One Biopharmaceuticals Engages With Patients Of All Ages, Particularly Those Facing Life-threatening Conditions, And Collaborates With Caregivers And The Oncology Community To Support Their Mission Of Redefining Hope In Cancer Treatment.